During the past decade, Koo Foundation Sun Yat-Sen Cancer Center conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 16 clinical trials were completed, i.e. on average, 45.7% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 13 clinical trials were completed. i.e. 76.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Koo Foundation Sun Yat-Sen Cancer Center" #1 sponsor was "Pfizer" with 9 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored and "National Health Research Institutes, Taiwan" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Koo Foundation Sun Yat-Sen Cancer Center" #1 collaborator was "Koo Foundation Sun Yat-Sen Cancer Center" with 3 trials as a collaborator, "National Taiwan University Hospital" with 3 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator, "Chang Gung Memorial Hospital" with 2 trials as a collaborator and "China Medical University Hospital" with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Koo Foundation Sun Yat-Sen Cancer Center" are "Breast Neoplasms" (8 trials), "Breast Cancer" (5 trials), "Metastatic Breast Cancer" (4 trials), "Ovarian Cancer" (4 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Koo Foundation Sun Yat-Sen Cancer Center" in a lesser frequency.

Most popular intervention types in "Koo Foundation Sun Yat-Sen Cancer Center" are "Drug" (38 trials), "Biological" (5 trials), "Other" (5 trials), "Device" (2 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (5 trials), "Placebo" (5 trials), "Avelumab" (3 trials), "Capecitabine" (3 trials) and "Palbociclib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Koo Foundation Sun Yat-Sen Cancer Center" are 29 trials for "All" genders and 15 trials for "Female" genders.

Currently, there are NaN active trials in "Koo Foundation Sun Yat-Sen Cancer Center". undefined are not yet recruiting, 9 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Koo Foundation Sun Yat-Sen Cancer Center, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Koo Foundation Sun Yat-Sen Cancer Center, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".